Prevalence of long QTc interval in methadone maintenance patients

Drug and Alcohol Dependence

Volumn 99, Issue 1-3, 2009, Pages 327-332

  Fonseca, Francina ^a   Marti Almor, Julio ^a   Pastor, Antoni ^b   Cladellas, Mercè ^a,c   Farré, Magí ^b,c   de la Torre, Rafael ^b,d   Torrens, Marta ^a,c  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Arrhythmia; Corrected QT interval; Methadone maintenance treatment (MMT)

Indexed keywords

METHADONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; ENANTIOMER; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR;

ADOLESCENT; ADULT; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LOGISTIC MODELS; LONG QT SYNDROME; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 57049108126     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.06.018     Document Type: Article

References (33)

1. Bazett H.C. An analysis of the time-relations of electrocardiograms. Heart 7 (1920) 353-370
2. Brugal M.T., Domingo-Salvany A., Puig R., Barrio G., Garcia de Olalla P., and de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 100 (2005) 981-989
3. Chinello P., Lisena F.P., Angeletti C., Boumis E., Papetti F., and Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J. Infect. 54 (2007) 597-602
4. Chugh S.S., Socoteanu C., Reinier K., Waltz J., Jui J., and Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am. J. Med. 121 (2008) 66-71
5. Cruciani R.A., Sekine R., Homel P., Lussier D., Yap Y., Suzuki Y., Schweitzer P., Yancovitz S.R., Lapin J.A., Shaiova L., Sheu R.G., and Portenoy R.K. Measurement of QTc in patients receiving chronic methadone therapy. J. Pain Symptom Manage. 29 (2005) 385-391
6. Eap C.B., Buclin T., and Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41 (2002) 1153-1193
7. Eap C.B., Crettol S., Rougier J.S., Schläpfer J., Sintra Grilo L., Déglon J.-J., Besson J., Croquette-Krokar M., Carrupt P.-A., and Abriel H. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin. Pharmacol. Ther. 81 (2007) 719-728
8. Eap C.B., Finkbeiner T., Gastpar M., Scherbaum N., Powell K., and Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)-/(S)-ratios and evidence of adaptative changes in methadone pharmacokinetics. Eur. J. Clin. Pharmacol. 50 (1996) 385-389
9. European Agency for the Evaluation of Medical Products. Committee for Propietary Medical Products, 2005. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. CHMP/ICH/2/04. http://www.emea.europa.eu/pdfs/human/ich/000204en.pdf [Accessed on 15 October 2007].
10. Festa A., D'Agostino R., Rautaharju P., Mykkamen L., and Haffner S.M. Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am. J. Cardiol. 86 (2000) 1117
11. Foster D.J.R., Somogyi A.A., White J.M., and Bochner F. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br. J. Clin. Pharmacol. 57 (2004) 742-756
12. Fredheim O.M., Borchgrevink P.C., Hegrenaes L., Kaasa S., Dale O., and Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J. Pain Symptom Manage. 32 (2006) 180-185
13. Gupta A., Lawrence A.T., Krishnan K., Kavinsky C.J., and Trohman R.G. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am. Heart J. 153 (2007) 891-899
14. Hothorn, T., Hornik, K., 2006. ExactRankTests: Exact Distributions for Rank and Permutation Tests. R package version 0.8-16.
15. Justo D., Gal-Oz A., Paran Y., Goldin Y., and Zeltser D. Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction 101 (2006) 1333-1338
16. Kelly T., Doble P., and Dawson M. Chiral separation of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP) by capillary electrophoresis using cyclodextrin derivatives. Electrophoresis 24 (2003) 2106-2110
17. Kornick C.A., Kilborn M.J., Santiago-Palma J., Schulman G., Thaler H.T., Keefe D.L., Katchman A.N., Pezzullo J.C., Ebert S.N., Woosley R.L., Payne R., and Manfredi P.L. QTc interval prolongation associated with intravenous methadone. Pain 105 (2003) 499-506
18. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., and Mehler P.S. Torsade de pointes associated with very-high-dose methadone. Ann. Intern. Med. 137 (2002) 501-504
19. Krantz M.J., Lowery C.M., Martell B.A., Gourevitch M.N., and Arnsten J.H. Effects of methadone on QT-interval dispersion. Pharmacotherapy 25 (2005) 1523-1529
20. Leavitt, S.B., 2005. Methadone-Drug* Interactions (*Medications, illicit drugs, & other substances). Addiction Treatment Forum. Third ed. Available at: http://www.atforum.com/SiteRoot/pages/addiction_resources/Drug_Interactions.pdf [Accessed 15 October 2007].
21. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., and Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur. Addict. Res. 11 (2005) 44-49
22. Martell B.A., Arnsten J.H., Krantz M.J., and Gourevitch M.N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am. J. Cardiol. 95 (2005) 915-918
23. Martell B.A., Arnsten J.H., Ray B., and Gourevitch M.N. The impact of methadone induction on cardiac conduction in opiate users. Ann. Intern. Med. 139 (2003) 154-155
24. Mitchell T.B., Dyer K.R., Newcombe D., Salter A., Somogyi A.A., Bochne F., and White J.M. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br. J. Clin. Pharmacol. 58 (2004) 609-617
25. Nordin C., Kohli A., Beca S., Zaharia V., Gran T., Leiden J., and Marantz P. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J. Electrocardiol. 39 (2006) 199-205
26. Pearson E.C., and Woosley R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol. Drug Saf. 14 (2005) 747-753
27. Peles E., Bodner G., Kreek M.J., Rados V., and Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients-a cross-sectional study. Addiction 102 (2007) 289-300
28. Piguet V., Desmeules J., Ehret G., Stoller R., and Dayer P. QT interval prolongation in patients on methadone with concomitant drugs. J. Clin. Psychopharmacol. 24 (2004) 446-448
29. Roden D.M. Long-QT syndrome. N. Engl. J. Med. 358 (2008) 169-176
30. Schwartz P.J., Moss A.J., Vincent G.M., and Crampton R.S. Diagnostic criteria for the long QT syndrome: an update. Circulation 88 (1993) 782-784
31. Service J.A., and Waring W.S. QT prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin. Toxicol. 46 (2008) 71-73
32. Skjervold B., Bathen J., and Spigset O. Methadone and the QT interval. Relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone. J. Clin. Psychopharmacol. 6 (2006) 687-689
33. Torrens M., Castillo C., San L., del Moral E., Gonzalez M.L., and de la Torre R. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend. 52 (1998) 193-200